Methods and compositions for treating, inhibiting, and/or preventing heterotopic ossification
AssigneeNorthwestern University
InventorsLixin Kan, John A. Kessler
Life of this patent
Estimating the term…
Abstract
Disclosed are methods and compositions for treating, inhibiting, and/or preventing heterotopic ossification in a subject in need thereof. Particularly disclosed are methods for treating, inhibiting, and/or preventing heterotopic ossification in a subject in need thereof by administering to the subject a therapeutic agent such as an immune checkpoint inhibitor and/or Fetuin-A or a variant thereof. Also disclosed are pharmaceutical compositions and pharmaceutical kits comprising an immune checkpoint inhibitor and/or Fetuin-A or a variant thereof for treating, inhibiting, and/or preventing heterotopic ossification in a subject in need thereof.
Claims13
A method for treating and/or inhibiting heterotopic ossification in a subject in need thereof, the method comprising administering to the subject an effective amount of an immune checkpoint inhibitor to treat and/or inhibit heterotopic ossification in the subject, wherein the immune checkpoint inhibitor is selected from the group consisting of an anti cluster of differentiation 152 (CD152) antibody, an anti programmed cell death protein 1 (PD-1) antibody, an anti programmed death-ligand 1 (PD-L1) antibody, and combinations thereof.
A method for treating and/or inhibiting heterotopic ossification in a subject in need thereof, the method comprising:
- (i) administering to the subject an effective amount of an immune checkpoint inhibitor to treat and/or inhibit heterotopic ossification in the subject, wherein the immune checkpoint inhibitor is selected from the group consisting of an anti CD152 antibody, an anti PD-1 antibody, an anti PD-L1 antibody and combinations thereof;
- and (ii) administering to the subject an effective amount of Fetuin-A to treat and/or inhibit heterotopic ossification in the subject, wherein the effective amount of the immune checkpoint inhibitor is administered to the subject before, concurrently with, or after the effective amount of the Fetuin-A is administered to the subject.
Dependencies are inferred from the claim text.